Agile Therapeutics Inc. [AGRX] Is Currently 8.87 above its 200 Period Moving Avg: What Dose This Mean?

Agile Therapeutics Inc. [NASDAQ: AGRX] stock went on an upward path that rose over 8.87% on Tuesday, amounting to a one-week price increase of more than 12.32%. The company report on August 17, 2020 that Agile Therapeutics Strengthens Executive Leadership Team with the Appointment of Paul Korner, MD, MBA, as Chief Medical Officer.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced the appointment of Paul Korner, MD, MBA, to the position of Chief Medical Officer. Dr. Korner is a board-certified obstetrician and gynecologist with more than 20 years of pharmaceutical and biotech industry experience, including significant experience within women’s healthcare. He will be responsible for supporting the commercial launch of Twirla®, advancing the Company’s internal pipeline and evaluating external growth opportunities. Dr. Korner will report to Al Altomari, Agile’s Chairman and Chief Executive Officer.

“We are excited to welcome Dr. Korner to Agile as we continue to strengthen and expand our senior leadership team,” said Al Altomari. “Dr. Korner’s private practice work and his deep pharmaceutical experience, particularly in leading multiple women’s health product approvals and launches, makes him a natural fit as we continue to advance Twirla towards commercial launch and broaden our women’s health portfolio for areas of unmet need.”.

Over the last 12 months, AGRX stock rose by 198.13%. The average equity rating for AGRX stock is currently 1.60, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $281.39 million, with 87.22 million shares outstanding and 67.15 million shares in the current float. Compared to the average trading volume of 1.70M shares, AGRX stock reached a trading volume of 1701895 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Agile Therapeutics Inc. [AGRX]:

Janney have made an estimate for Agile Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 12, 2019. While these analysts kept the previous recommendation, Maxim Group raised their target price to Buy. The new note on the price target was released on November 29, 2018, representing the official price target for Agile Therapeutics Inc. stock.

The Average True Range (ATR) for Agile Therapeutics Inc. is set at 0.17 The Price to Book ratio for the last quarter was 3.43, with the Price to Cash per share for the same quarter was set at 0.99.

AGRX Stock Performance Analysis:

Agile Therapeutics Inc. [AGRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.32. With this latest performance, AGRX shares gained by 31.28% in over the last four-week period, additionally plugging by 1.43% over the last 6 months – not to mention a rise of 198.13% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AGRX stock in for the last two-week period is set at 70.31, with the RSI for the last a single of trading hit 77.36, and the three-weeks RSI is set at 65.65 for Agile Therapeutics Inc. [AGRX]. The present Moving Average for the last 50 days of trading for this stock 2.69, while it was recorded at 2.98 for the last single week of trading, and 2.60 for the last 200 days.

Insight into Agile Therapeutics Inc. Fundamentals:

Return on Total Capital for AGRX is now -57.07, given the latest momentum, and Return on Invested Capital for the company is -56.45. Return on Equity for this stock declined to -56.45, with Return on Assets sitting at -51.73. When it comes to the capital structure of this company, Agile Therapeutics Inc. [AGRX] has a Total Debt to Total Equity ratio set at 0.38. Additionally, AGRX Total Debt to Total Capital is recorded at 0.37, with Total Debt to Total Assets ending up at 0.35.

Reflecting on the efficiency of the workforce at the company, Agile Therapeutics Inc. [AGRX] managed to generate an average of -$1,240,400 per employee.Agile Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 13.70 and a Current Ratio set at 13.70.

AGRX Stock EPS

With the latest financial reports released by the company, Agile Therapeutics Inc. posted -0.08/share EPS, while the average EPS was predicted by analysts to be reported at -0.08/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AGRX.

Agile Therapeutics Inc. [AGRX] Insider Position Details

There are presently around $123 million, or 50.80% of AGRX stock, in the hands of institutional investors. The top three institutional holders of AGRX stocks are: PERCEPTIVE ADVISORS LLC with ownership of 15,919,925, which is approximately 0.004% of the company’s market cap and around 0.80% of the total institutional ownership; BLACKROCK INC., holding 5,137,173 shares of the stock with an approximate value of $16.39 million in AGRX stocks shares; and VANGUARD GROUP INC, currently with $12.48 million in AGRX stock with ownership of nearly 14.854% of the company’s market capitalization.

Positions in Agile Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 62 institutional holders increased their position in Agile Therapeutics Inc. [NASDAQ:AGRX] by around 10,063,693 shares. Additionally, 28 investors decreased positions by around 4,518,634 shares, while 11 investors held positions by with 23,985,006 shares. The mentioned changes placed institutional holdings at 38,567,333 shares, according to the latest SEC report filing. AGRX stock had 34 new institutional investments in for a total of 1,913,819 shares, while 19 institutional investors sold positions of 2,314,772 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam